Your browser doesn't support javascript.
loading
PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCα/BRAF/MEK/ERK signaling pathway.
Cao, Huijun; Wang, Zhiqiang; Wang, Ying; Ye, Lijuan; Li, Ruilei; Xue, Yuanbo; Li, Ke; Di, Tiannan; Li, Tao; Fan, Zonglin; Liu, Yanyan; Guo, Jiyin; Yao, Hong; Ge, Chunlei.
Affiliation
  • Cao H; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Wang Z; Department of Radiotherapy Oncology, The First Affiliated Hospital of Kunming Medical University, First School of Clinical Medicine, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Wang Y; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Ye L; Department of Pathology, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Li R; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Xue Y; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Li K; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Di T; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Li T; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Fan Z; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Liu Y; Department of Medical Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Guo J; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Yao H; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
  • Ge C; Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital, Kunming Medical University, Xishan, Kunming, Yunnan 650000, P.R. China.
Int J Oncol ; 61(6)2022 Dec.
Article in En | MEDLINE | ID: mdl-36263632
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma of Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Int J Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: Greece
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma of Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Int J Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: Greece